logo-loader

Silence Therapeutics boosted by news of licensee drug trials

Published: 15:26 30 Oct 2015 GMT

microscope
Trials will begin in December

Silence Therapeutics (LON:SLN) shares moved higher on Friday afternoon after it highlighted news that two new clinical trials are set to go ahead.

It pointed to information released by SBI Holdings, the owner of Quark Pharmaceuticals, which has licensed the AIM quoted company’s proprietary technology, which reveals that trails will begin in December 2015.

There will be a Phase 3 trial for a renal delayed graft, and a Phase 2 trial for acute kidney injury.

In a stock market statement, Silence described it as “further validation” of the proprietary technology which also underpins its own drug development pipeline.

For both indications, Novartis has an option to licence the drugs.

Silence would be due milestone payments through the continued development of the drugs that use its technology, but, it has no future financial obligations to any of the programmes.

On AIM, Silence Therapeutics shares gained 4.75p, 2.8%, to trade at 174.75p each.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 51 minutes ago